TenAces Biosciences
Molecular Glue Therapeutics
StartupTenAces Biosciences is a Rehovot-based startup in the Health Tech & Life Sciences sector, established in 2024. Molecular Glue Therapeutics. TenAces Biosciences was founded by Arnout Schepers. Key investors include AION Labs, Israel Biotech Fund. The company has 1-10 employees. Core technologies: Artificial Intelligence, Machine Learning, Biologicals, Molecules.
The company follows a B2B business model. Product stage: R&D.
- StageSeed
- ProductR&D
- ModelB2B
- Employees1-10
- HQRehovot
- Last RoundUndisclosed
- AION Labs
- Israel Biotech Fund
Arnout SchepersFounder & CEO
1 article covered by sources including www.prnewswire.com.
What does TenAces Biosciences do?
TenAces Biosciences is a biopharmaceutical company focused on the development of molecular glue therapeutics. The molecular glues are small molecules that can induce or stabilize the interaction between an E3 ligase and a target protein. This enhanced binding accelerates the tagging with ubiquitin, and subsequent removal of the target protein by the proteasome. The company's approach, based on machine learning, 3D modeling and virtual compound screening, allows for the development of rationally designed molecular glues for a wide range of diseases.
Who founded TenAces Biosciences?
TenAces Biosciences was founded in 2024 by Arnout Schepers (Founder & CEO).
What sector is TenAces Biosciences in?
TenAces Biosciences operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Artificial Intelligence, Machine Learning, Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is TenAces Biosciences located?
TenAces Biosciences is based in Rehovot, Israel.